Revue des maladies respiratoires · 2011
[Treatment of distal airways involvement in COPD].
Аннотация на английскомСтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Devillier P, Jebrak G, Morel H, Chinet T, Didier A, Roche N
Аннотация
INTRODUCTION: The current pharmacological treatment of COPD provides only partial beneficial effects on symptoms, exercise tolerance, frequency of exacerbations and quality of life. This could be related to poor targeting of the distal airways by current treatments, yet these airways are particularly involved in airflow obstruction and its consequences such as hyperinflation.
BACKGROUND: Many treatments used in COPD could have effects on distal airways, including bronchodilators, corticosteroids, mucolytics and antibiotics. However, these possible effects remain poorly understood.
VIEWPOINTS: New treatments targeting more specifically the mechanisms of inflammation, oxidative stress and tissue remodeling that characterize COPD, could prove useful in its management, but most are still only in the early stages of their development. Advances could also come from improvements in inhalation devices, delivering more of the medication to the distal airways.
CONCLUSIONS: Improvement in the management of COPD could come from progress in terms of both molecules and their mode of administration.
BACKGROUND: Many treatments used in COPD could have effects on distal airways, including bronchodilators, corticosteroids, mucolytics and antibiotics. However, these possible effects remain poorly understood.
VIEWPOINTS: New treatments targeting more specifically the mechanisms of inflammation, oxidative stress and tissue remodeling that characterize COPD, could prove useful in its management, but most are still only in the early stages of their development. Advances could also come from improvements in inhalation devices, delivering more of the medication to the distal airways.
CONCLUSIONS: Improvement in the management of COPD could come from progress in terms of both molecules and their mode of administration.
Предметные рубрики MeSH
Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Bacterial AgentsAnti-Inflammatory AgentsBronchodilator AgentsCholinergic AntagonistsDisease ManagementDisease ProgressionDrug InteractionsDrug Therapy, CombinationEquipment DesignExpectorantsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsNebulizers and VaporizersPhosphodiesterase 4 InhibitorsProtein Kinase InhibitorsPulmonary AlveoliPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicRespiratory Tract InfectionsTherapies, Investigational